relapsed or refractory large B-cell lymphoma

Kite publishes Phase II data for Yescarta in treating B-cell lymphoma
Clinical Trials Arena
Mon, 09/18/23 - 09:53 am
Gilead Sciences
Kite Pharma
Yescarta
clinical trials
CAR-T
relapsed or refractory large B-cell lymphoma
Kite's Yescarta CAR T-cell Therapy Shows Extended Survival in Relapsed/Refractory Large B-cell Lymphoma
Businesswire
Tue, 06/6/23 - 10:11 am
ASCO 2023
Gilead Sciences
Kite Pharma
Yescarta
relapsed or refractory large B-cell lymphoma
AbbVie's Roche-rivaling blood cancer bispecific gets FDA priority review, triggering Genmab payday
Fierce Biotech
Mon, 11/21/22 - 10:12 am
AbbVie
Genmab
FDA
Roche
epcoritamab
bispecific antibodies
relapsed or refractory large B-cell lymphoma